Harreiter J, Just I, Leutner M, Bastian M, et al. Combined EXENatide and DApagliflozin has no additive effects on reduction of
hepatocellular lipids despite better glycemic control in patients with type 2
diabetes mellitus treated with metformin -EXENDA, a 24 week, prospective,
randomized, placebo-co Diabetes Obes Metab 2021 Jan 19. doi: 10.1111/dom.14319.
PMID: 33464703